Peer-reviewed veterinary case report
Pimobendan effects on heart ultrasound in dogs with silent mitral
By Ouellet, M et al.·Published in Journal of veterinary internal medicine·2009·Companion Animal Research Group of the Faculty of Veterinary Medicine, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease.
- Species:
- dog
Plain-English summary
A group of 24 dogs with early-stage mitral valve disease (MVD) were given a medication called pimobendan to see if it would help improve their heart function. While the dogs showed some improvement in heart pumping ability shortly after starting the treatment, these benefits did not last over the six-month study period. Unfortunately, pimobendan did not reduce the severity of the heart condition in the long term. If your dog has been diagnosed with MVD, it's important to discuss ongoing treatment options with your veterinarian.
People also search for: dog mitral valve disease treatment · pimobendan for dogs · heart medication for dogs
Abstract
BACKGROUND: Pimobendan (PIMO) is a novel inodilator that has shown promising results in the treatment of advanced mitral valve disease (MVD), but little is known about its hemodynamic effects, especially regarding the mitral regurgitant volume in naturally occurring MVD. HYPOTHESIS: The addition of pimobendan to treatment decreases the regurgitant fraction (RF) in dogs with asymptomatic MVD. ANIMALS: Twenty-four client-owned dogs affected by International Small Animal Cardiac Health Council class Ib MVD. METHODS: Prospective, blinded, and controlled clinical trial. Dogs were assigned to a PIMO treatment group (n = 19) (0.2-0.3 mg/kg q12h) or a control group (n = 5). Echocardiographic evaluations were performed over a 6-month period. RESULTS: The addition of PIMO to treatment did not decrease the RF of dogs affected by asymptomatic class 1b MVD over the study period (P= .85). There was a significant increase in the ejection fraction of the PIMO treated dogs at 30 days (80.8 +/- 1.42 versus 69.0 +/- 2.76, corrected P= .0064), and a decrease in systolic left ventricular diameter (corrected P= .011) within the PIMO group compared with baseline. However, this improvement in systolic function was not sustained over the 6-month trial period. CONCLUSION AND CLINICAL IMPORTANCE: This study did not identify beneficial long-term changes in the severity of mitral regurgitation after addition of PIMO to angiotensin converting enzyme inhibitor treatment of dogs with asymptomatic MVD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19143935/